Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Auricular Vagal Neuromodulation for Depression and Anxiety in Substance Use Disorder

NCT: NCT07814755 · NOT_YET_RECRUITING

NCT IDNCT07814755
StatusNOT_YET_RECRUITING
Start Date2026-10
Completion2029-10
SponsorDaisy Thompson-Lake (OTHER)
First posted
Last updated

Brief Summary

This pilot study will evaluate whether home-based auricular vagal neuromodulation therapy (AVNT) is practical, acceptable, and well tolerated for adults receiving treatment for substance use disorder. Participants will use a handheld device that delivers mild electrical stimulation to the ear for approximately 60 minutes each day over 30 days. Researchers will examine whether participants can successfully use the device as directed and complete study procedures. The study will also explore whether use of the device is associated with changes in depression, anxiety, sleep problems, and substance craving.

Frequently Asked Questions

What is Auricular Vagal Neuromodulation for Depression and Anxiety in Substance Use Disorder?

Auricular Vagal Neuromodulation for Depression and Anxiety in Substance Use Disorder is a clinical trial registered under NCT07814755. Current status: NOT_YET_RECRUITING.

What is the status of NCT07814755?

The current status of NCT07814755 (Auricular Vagal Neuromodulation for Depression and Anxiety in Substance Use Disorder) is: NOT_YET_RECRUITING.

When did Auricular Vagal Neuromodulation for Depression and Anxiety in Substance Use Disorder start?

Auricular Vagal Neuromodulation for Depression and Anxiety in Substance Use Disorder started on 2026-10.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.